Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 28 peer-reviewed journal articles Updated
Oncology

The Roadmap for Care: Standard Treatment for RCC

At a Glance

Treatment for Renal Cell Carcinoma (RCC) depends on the tumor's stage. Localized tumors are typically treated with partial nephrectomy, while high-risk patients may receive post-surgery pembrolizumab. Advanced RCC is treated using immunotherapy and targeted drug combinations based on risk score.

Treating Renal Cell Carcinoma (RCC) is no longer a one-size-fits-all process. Depending on the size, location, and stage of your tumor, your medical team will choose from a variety of tools, ranging from careful monitoring to advanced immunotherapy combinations [1].

Treatment for Localized Disease (Stage I & II)

When the cancer is confined to the kidney, the primary goal is often the removal or destruction of the tumor while preserving as much healthy kidney function as possible.

  • Partial Nephrectomy (PN): This is the “gold standard” for small tumors (cT1, ≤7 cm) [2]. The surgeon removes only the tumor and a small margin of healthy tissue. This helps protect your long-term kidney health and reduces the risk of heart disease later in life [3][1].
  • Thermal Ablation: For small masses (usually <4 cm) in patients who are older or have other health risks, doctors may use extreme heat or cold to destroy the tumor without traditional surgery [4][5].
  • Active Surveillance: If a tumor is very small and likely slow-growing, your doctor may recommend regular scans and monitoring instead of immediate surgery, especially if the risks of surgery outweigh the benefits [1][6].

Treatment for Locally Advanced Disease (Stage III)

If your cancer is larger or has started to grow into the major veins leaving the kidney or the surrounding fat (Stage III), the primary treatment is usually a Radical Nephrectomy [7][8]. In this surgery, the entire kidney and sometimes surrounding lymph nodes are removed to ensure no cancer is left behind.

The “High-Risk” Adjuvant Setting

If you have surgery to remove your tumor but your pathology report shows features that put you at a high risk of the cancer returning—such as a large tumor size, high grade, or sarcomatoid features—you may be a candidate for adjuvant therapy [9][10].

Current standards recommend one year of pembrolizumab (an immunotherapy) after surgery for high-risk patients [9][11]. This has been shown to significantly reduce the risk of the cancer coming back and improve overall survival [9][12].

Advanced and Metastatic Disease (Stage IV)

For cancer that has spread beyond the kidney, the focus shifts to systemic therapy (drugs that travel through the entire body). Treatment is chosen based on your IMDC risk category (Favorable, Intermediate, or Poor), which is determined by specific blood tests and your physical health [13][14].

First-Line Combinations

The current standard of care involves “doublet” therapies that combine different types of drugs:

  1. IO + TKI: An Immune Checkpoint Inhibitor (IO) plus a Tyrosine Kinase Inhibitor (TKI). Common pairs include pembrolizumab + axitinib, nivolumab + cabozantinib, or pembrolizumab + lenvatinib [15][16][17].
  2. IO + IO: Two different immunotherapies, specifically nivolumab + ipilimumab. This is a standard option for patients in the Intermediate or Poor risk groups [18][19].

What About Surgery for Metastatic Disease?

A surgery called cytoreductive nephrectomy (removing the primary kidney tumor even if the cancer has spread elsewhere) is no longer recommended for everyone [20][21]. It is now most often considered for patients who respond very well to initial drug therapy or those with a very large primary tumor and only a small amount of spread elsewhere [22][23].

Managing Treatment Side Effects

It is vital to understand that IO and TKI therapies come with specific side effect profiles. You must report any new symptoms to your medical team immediately, as early intervention is key to managing them safely [24].

  • IO Side Effects: Because immunotherapies stimulate the immune system, they can cause immune-mediated adverse events where the body attacks healthy organs. This can manifest as pneumonitis (lung inflammation causing a cough/shortness of breath) or colitis (severe diarrhea) [25][26].
  • TKI Side Effects: TKIs often cause issues related to blood vessels and tissue repair, including severe high blood pressure (hypertension), diarrhea, and hand-foot syndrome (redness, swelling, and pain on the palms of the hands and soles of the feet) [24][27].

Finding a surgeon with high-volume experience in partial nephrectomy and a medical oncologist who specializes in kidney cancer is the best way to ensure your treatment plan reflects these rapidly evolving standards [28].

Common questions in this guide

What is the standard treatment for a small, localized kidney tumor?
For small tumors confined to the kidney, a partial nephrectomy is often considered the gold standard. This surgery removes the tumor while preserving as much healthy kidney tissue as possible, which helps protect your long-term kidney function.
Do I need treatment after surgery for renal cell carcinoma?
If your tumor had high-risk features like a large size or sarcomatoid cells, your doctor might recommend adjuvant therapy. The current standard is one year of an immunotherapy called pembrolizumab to help reduce the risk of the cancer returning.
How do doctors choose treatments for advanced or metastatic kidney cancer?
Treatment for advanced RCC relies on systemic therapies that travel throughout the body. Your care team will determine your IMDC risk category through blood tests and your physical health to choose the best combination of immunotherapy and targeted therapy drugs for your specific profile.
Is surgery recommended if my kidney cancer has already spread?
Removing the primary kidney tumor when cancer has spread elsewhere, known as a cytoreductive nephrectomy, is no longer recommended for everyone. It is typically reserved for patients who respond very well to initial drug therapies or have very minimal spread.
What are the common side effects of kidney cancer medications?
Immunotherapies can cause immune-related side effects like lung inflammation or severe diarrhea. Targeted therapies, known as TKIs, frequently cause high blood pressure, diarrhea, and hand-foot syndrome, which involves severe redness and pain on the palms and soles.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the R.E.N.A.L. nephrometry score of my tumor, and how does that affect my chances for a successful partial nephrectomy?
  2. 2.How many partial nephrectomies do you perform each year?
  3. 3.Am I considered 'high-risk' according to the KEYNOTE-564 criteria, and should I start adjuvant pembrolizumab?
  4. 4.What is my IMDC risk score (Favorable, Intermediate, or Poor), and how does that influence our choice of first-line therapy?
  5. 5.If we start with an IO/TKI combination, which TKI (axitinib, lenvatinib, or cabozantinib) is most appropriate for my health profile?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (28)
  1. 1

    Comparative efficacy and safety of ablative therapies in the management of primary localised renal cell carcinoma: a systematic review and meta-analysis.

    Huang RS, Chow R, Benour A, et al.

    The Lancet. Oncology 2025; (26(3)):387-398 doi:10.1016/S1470-2045(24)00731-9.

    PMID: 39922208
  2. 2

    Benefit of nephron sparing surgery translates into lower cancer specific mortality in patients with localized renal cell carcinoma.

    Mistretta FA, Mazzone E, Knipper S, Karakiewicz PI

    Annals of translational medicine 2018; (6(Suppl 2)):S104 doi:10.21037/atm.2018.11.37.

    PMID: 30740425
  3. 3

    National Norwegian Practice Patterns for Surgical Treatment of Kidney Cancer Tumors ≤7cm: Adherence to Changes in Guidelines May Improve Overall Survival.

    Hjelle KM, Johannesen TB, Bostad L, et al.

    European urology oncology 2018; (1(3)):252-261 doi:10.1016/j.euo.2018.04.001.

    PMID: 31102628
  4. 4

    Percutaneous Microwave Ablation versus Laparoscopic Partial Nephrectomy for cT1a Renal Cell Carcinoma: A Propensity-matched Cohort Study of 1955 Patients.

    Yu J, Zhang X, Liu H, et al.

    Radiology 2020; (294(3)):698-706 doi:10.1148/radiol.2020190919.

    PMID: 31961239
  5. 5

    Percutaneous microwave ablation of renal cell carcinoma: practice guidelines of the ultrasound committee of Chinese medical association, interventional oncology committee of Chinese research hospital association.

    Yu J, Yu XL, Cheng ZG, et al.

    International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2020; (37(1)):827-835 doi:10.1080/02656736.2020.1779356.

    PMID: 32635839
  6. 6

    Renal mass biopsy - a practical and clinicopathologically relevant approach to diagnosis.

    Mansour H, Tran-Dang MA, Walkden M, et al.

    Nature reviews. Urology 2025; (22(1)):8-25 doi:10.1038/s41585-024-00897-5.

    PMID: 38907039
  7. 7

    How to Deal with Renal Cell Carcinoma >7 cm: Radical Surgery.

    Grimm MO, Leucht K

    European urology open science 2021; (33()):81-82 doi:10.1016/j.euros.2021.09.001.

    PMID: 34632424
  8. 8

    Predictors of Recurrence for T3a RCC: A Recurring Conundrum.

    Leopold Z, Srivastava A, Singer EA

    Diagnostics (Basel, Switzerland) 2020; (10(11)) doi:10.3390/diagnostics10110983.

    PMID: 33233477
  9. 9

    Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.

    Choueiri TK, Tomczak P, Park SH, et al.

    The New England journal of medicine 2024; (390(15)):1359-1371 doi:10.1056/NEJMoa2312695.

    PMID: 38631003
  10. 10

    Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.

    Choueiri TK, Tomczak P, Park SH, et al.

    The New England journal of medicine 2021; (385(8)):683-694 doi:10.1056/NEJMoa2106391.

    PMID: 34407342
  11. 11

    Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitors and Subsequent Therapy for Renal Cell Carcinoma.

    Bedke J, Ghanem YA, Albiges L, et al.

    European urology 2025; (87(4)):491-496 doi:10.1016/j.eururo.2025.01.014.

    PMID: 39904712
  12. 12

    Adjuvant and Neoadjuvant Therapy in Renal Cell Carcinoma.

    Kuusk T, Bex A

    Hematology/oncology clinics of North America 2023; (37(5)):907-920 doi:10.1016/j.hoc.2023.05.020.

    PMID: 37369611
  13. 13

    An Update on Predictive Biomarkers in Metastatic Renal Cell Carcinoma.

    Dudani S, Savard MF, Heng DYC

    European urology focus 2020; (6(1)):34-36 doi:10.1016/j.euf.2019.04.004.

    PMID: 31010693
  14. 14

    Risk Stratification and Treatment Algorithm of Metastatic Renal Cell Carcinoma.

    Grimm MO, Leucht K, Foller S

    Journal of clinical medicine 2021; (10(22)) doi:10.3390/jcm10225339.

    PMID: 34830621
  15. 15

    Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.

    Bedke J, Albiges L, Capitanio U, et al.

    European urology 2021; (79(3)):339-342 doi:10.1016/j.eururo.2020.12.005.

    PMID: 33357997
  16. 16

    Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.

    Laccetti AL, Garmezy B, Xiao L, et al.

    Cancer medicine 2021; (10(7)):2341-2349 doi:10.1002/cam4.3812.

    PMID: 33650321
  17. 17

    Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: a meta-analysis.

    Rizzo A, Mollica V, Santoni M, et al.

    Immunotherapy 2021; (13(9)):783-793 doi:10.2217/imt-2021-0005.

    PMID: 33906376
  18. 18

    Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

    Motzer RJ, Tannir NM, McDermott DF, et al.

    The New England journal of medicine 2018; (378(14)):1277-1290 doi:10.1056/NEJMoa1712126.

    PMID: 29562145
  19. 19

    New First Line Treatment Options of Clear Cell Renal Cell Cancer Patients with PD-1 or PD-L1 Immune-Checkpoint Inhibitor-Based Combination Therapies.

    Grimm MO, Leucht K, Grünwald V, Foller S

    Journal of clinical medicine 2020; (9(2)) doi:10.3390/jcm9020565.

    PMID: 32092974
  20. 20

    Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma.

    Bex A, Albiges L, Ljungberg B, et al.

    European urology 2018; (74(6)):805-809 doi:10.1016/j.eururo.2018.08.008.

    PMID: 30177291
  21. 21

    Individualised Indications for Cytoreductive Nephrectomy: Which Criteria Define the Optimal Candidates?

    Larcher A, Wallis CJD, Bex A, et al.

    European urology oncology 2019; (2(4)):365-378 doi:10.1016/j.euo.2019.04.007.

    PMID: 31109902
  22. 22

    Deferred cytoreductive nephrectomy in the management of metastatic renal cell carcinoma: A systematic review and meta-analysis.

    Britton CJ, Andrews JR, Wallis CJD, et al.

    Urologic oncology 2023; (41(3)):125-136 doi:10.1016/j.urolonc.2022.09.021.

    PMID: 38832909
  23. 23

    Cytoreductive nephrectomy: future directions.

    Margulis V, Hakimi AA

    Current opinion in urology 2019; (29(5)):540-541 doi:10.1097/MOU.0000000000000662.

    PMID: 31305272
  24. 24

    Risk of toxicity with immunotherapy-tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials.

    Rizzo A, Mollica V, Santoni M, et al.

    Future oncology (London, England) 2022; (18(5)):625-634 doi:10.2217/fon-2021-0888.

    PMID: 34927453
  25. 25

    Pembrolizumab-induced encephalitis in a patient with renal cell carcinoma post nephrectomy: A case report.

    Sharma A, Chapagain A, Kharel S, et al.

    SAGE open medical case reports 2023; (11()):2050313X221149827 doi:10.1177/2050313X221149827.

    PMID: 36686204
  26. 26

    Pembrolizumab Induced Recall Dermatitis Occurring 5 Years After Radiotherapy.

    Cushman CJ, Abaleka F, Ibrahim AF, et al.

    Reports (MDPI) 2024; (7(4)) doi:10.3390/reports7040091.

    PMID: 40757683
  27. 27

    Incidence and impact of immune combination therapies adverse events in advanced renal cell carcinoma patients.

    Catalano M, Venturi G, Salfi A, et al.

    Immunotherapy 2025; (17(4)):247-256 doi:10.1080/1750743X.2025.2482510.

    PMID: 40152649
  28. 28

    Impact of Positive Surgical Margins After Partial Nephrectomy.

    Carvalho JAM, Nunes P, Tavares-da-Silva E, et al.

    European urology open science 2020; (21()):41-46 doi:10.1016/j.euros.2020.08.006.

    PMID: 34337467

This page outlines standard treatment options for renal cell carcinoma for informational purposes only. Always consult your medical oncologist or urologist to determine the safest and most effective treatment plan for your specific stage and health profile.

Get notified when new evidence is published on Renal cell carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.